Cytomegalovirus (CMV) end-organ disease
CMV · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
CMV causes end-organ disease (retinitis, colitis, pneumonitis, encephalitis) mainly in advanced HIV, transplant recipients and other immunosuppressed hosts. Prompt antiviral therapy prevents irreversible damage, particularly vision loss in retinitis.
Red flags
- Any visual blurring/floaters in immunosuppressed (retinitis)
- Haematochezia or perforation signs (colitis)
- Hypoxia with diffuse infiltrates (pneumonitis)
- Altered consciousness (encephalitis/ventriculitis)
- Rising viral load despite therapy (resistance)
Assessment
Differential diagnosis
- Other opportunistic infection (toxoplasma, PCP, cryptococcus)
- Immune reconstitution uveitis
- HIV-related or drug-induced colitis
- Rejection in transplant recipients
- Other viral end-organ disease (HSV, adenovirus)
Investigations
- CMV PCR (blood viral load) and tissue PCR where applicable
- Dilated fundoscopy by ophthalmology for retinitis
- Endoscopy with biopsy for colitis (CMV inclusions/immunostain)
- CD4 count and HIV viral load
- Bronchoalveolar lavage for pneumonitis
- CSF CMV PCR for neurological disease
Management
- Identify host immunosuppression and localise end-organ involvement
- Confirm with CMV PCR and tissue histology/immunostaining where feasible
- Arrange urgent ophthalmology review if any visual symptoms
- Start systemic antiviral therapy promptly (induction then maintenance)
- For sight-threatening retinitis consider intravitreal therapy plus systemic
- Reduce immunosuppression where safe in transplant recipients
- In HIV, start or optimise ART (watch for immune recovery uveitis)
- Monitor CMV viral load response and renal/marrow toxicity of antivirals
- Continue maintenance until immune recovery (e.g. CD4 over 100 for 3-6 months)
- Screen for and manage antiviral resistance if poor response
- Provide supportive care and manage complications
- Arrange ophthalmology follow-up for retinal detachment risk
Drugs & doses
Ganciclovir 5 mg/kg IV every 12 h induction for 14-21 days
Valganciclovir 900 mg PO twice daily induction then 900 mg once daily maintenance
Foscarnet 60 mg/kg IV every 8 h (ganciclovir resistance/intolerance)
Ganciclovir intravitreal injection for sight-threatening retinitis (adjunct)
Disposition
Admit for induction if severe; urgent ophthalmology; specialist ID/transplant co-management.
Complications & pitfalls
- Irreversible blindness and retinal detachment
- Gastrointestinal haemorrhage/perforation
- Immune recovery uveitis after ART
- Marrow suppression (ganciclovir) and nephrotoxicity (foscarnet)
- Antiviral resistance
Exam pearls
- Zone 1 retinitis threatening the macula/optic nerve needs intravitreal plus systemic therapy
- Valganciclovir oral bioavailability allows outpatient induction in stable retinitis
- Monitor neutrophils on ganciclovir; add G-CSF if needed
- In HIV, restoring immunity is the definitive treatment
- Resistance testing (UL97/UL54) guides switch to foscarnet/cidofovir
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.